Filter Results:
(925)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,282)
- People (5)
- News (172)
- Research (925)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Sort by
- March 2010 (Revised May 2012)
- Case
Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration
By: Karim R. Lakhani and Paul R. Carlile
This case presents the Myelin Repair Foundation's accelerated research collaboration model for drug discovery. It highlights the challenges of building a multi-disciplinary and multi-institutional research collaboration that is attempting to create a treatment for... View Details
Keywords: Research and Development; Intellectual Property; Risk and Uncertainty; Strategic Planning; Collaborative Innovation and Invention; Health Disorders; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lakhani, Karim R., and Paul R. Carlile. "Myelin Repair Foundation: Accelerating Drug Discovery Through Collaboration." Harvard Business School Case 610-074, March 2010. (Revised May 2012.)
- 18 Nov 2014
- First Look
First Look: November 18
were the strengths and challenges facing this model? How would the model evolve in the future? And how would new, similar collaboration models surfacing at other major pharmaceutical companies pose a threat to the Pfizer model? Purchase... View Details
Keywords: Sean Silverthorne
- 21 Nov 2006
- First Look
First Look: November 21, 2006
cost to identify and investigate. The Effect of File Sharing on Record Sales: An Empirical Analysis Authors:Felix Oberholzer-Gee and Koleman Strumpf Periodical:Journal of Political Economy (forthcoming) Abstract For industries ranging from software to View Details
Keywords: Sean Silverthorne
- 12 Oct 2006
- First Look
First Look: October 12, 2006
pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care and a shinier future for human well-being. Pre-order this book:... View Details
Keywords: Sean Silverthorne
- 28 Aug 2017
- Research & Ideas
Should Industry Competitors Cooperate More to Solve World Problems?
to be innovative, really providing service to customers and attracting top talent. They are now becoming utilities, facing an incredible amount of regulation largely because of their own conduct failures. Third, they could reduce risk from exposure to major scandals.... View Details
- January 2017 (Revised March 2017)
- Case
Royal DSM: From Continuous Transformation to Organic Growth
By: William W. George, Carin-Isabel Knoop and Amram Migdal
Royal DSM CEO Feike Sijbesma was pondering the challenges of shifting DSM’s global organization from the constant transformations of the past 100 years to creating organic growth. When Sijbesma took the helm as CEO in 2007, he further pushed and completed the company’s... View Details
Keywords: Organic Growth; Organizational Change; M＆A; Mergers And Acquisitions; Divestment; Business Ventures; Business Divisions; Business Growth and Maturation; Restructuring; Change; Change Management; Transformation; Transition; Engineering; Chemicals; Mining; Ethics; Values and Beliefs; Finance; Capital Markets; Financial Markets; Food; Globalization; Global Strategy; Globalized Firms and Management; Globalized Markets and Industries; Health; Nutrition; History; Leadership; Leadership Development; Leadership Style; Leading Change; Management; Business or Company Management; Growth and Development Strategy; Growth Management; Management Practices and Processes; Management Style; Organizations; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Change and Adaptation; Organizational Culture; Organizational Design; Ownership; Public Ownership; Performance; Strategy; Adaptation; Consolidation; Corporate Strategy; Value; Value Creation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Europe; Netherlands
George, William W., Carin-Isabel Knoop, and Amram Migdal. "Royal DSM: From Continuous Transformation to Organic Growth." Harvard Business School Case 317-063, January 2017. (Revised March 2017.)
- 23 May 2017
- First Look
First Look at New Ideas and Research: May 23, 2017
of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and structured it into 16 distinct business units ranging from animal health to oncology while... View Details
Keywords: Carmen Nobel
- 09 Feb 2016
- First Look
February 9, 2016
challenges as it seeks to continue its growth. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/816013-PDF-ENG Harvard Business School Case 316-010 The Allergan Board Under Fire (A) In 2014, the Allergan Inc. board of directors received a surprise takeover... View Details
Keywords: Sean Silverthorne
- 26 Sep 2006
- First Look
First Look: September 26, 2006
patient needs and working backwards to develop profitable solutions rather than starting with the government, pharmaceutical or healthcare industry or NGO. The examination is undertaken on two levels, a macro level that focuses on... View Details
Keywords: Sean Silverthorne
- July 2017 (Revised July 2019)
- Supplement
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B)
By: Nori Gerardo Lietz and Ricardo Andrade
The B Case of "Dr. My Eyes" provides the answer as to what happened after the ending fact pattern in Case A and the imminent choices faced by the protagonist in the primary case. At the end of the Case A, Bess Weatherman of Warburg Pincus, must chose one option of two... View Details
Keywords: Private Equity; Health Care and Treatment; Mergers and Acquisitions; Corporate Governance; Decision Choices and Conditions; Outcome or Result; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (B). Harvard Business School Supplement 218-029, July 2017. (Revised July 2019.)
- July 2016 (Revised July 2019)
- Teaching Plan
Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)
By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
- April 2016 (Revised July 2019)
- Case
"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers ＆ Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
- August 2003
- Teaching Note
Pharmacyclics: Financing Research and Development (TN)
By: Malcolm P. Baker and Richard S. Ruback
Teaching Note for (9-201-056). View Details
- Research Summary
Overview
By: Andy Wu
How can technology entrepreneurs build competitive advantage from the ground up? Professor Andy Wu conducts scholarly research and develops course materials that document how technology entrepreneurs can (1) organize for innovation to create new market opportunities... View Details
Keywords: Strategy; Entrepreneurship; Venture Capital; Growth Management; Organizational Design; Organizational Structure; Technology Platform; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; China; Southeast Asia; South Asia
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term... View Details
- 05 Sep 2007
- First Look
First Look: September 5, 2007
value, or derail deals altogether. Consider, for example, the pharmaceutical company that deadlocked with a supplier over the issue of exclusivity in an ingredient purchase. Believing it was a ploy to raise the price, the drug maker upped... View Details
Keywords: Martha Lagace
- 21 Apr 2014
- Research & Ideas
Bio-Piracy: When Western Firms Usurp Eastern Medicine
communities that traditionally use the herb. The paper cites two key examples of local communities benefiting from a firm's herbal patent. In one case, members of Indian Kani tribe received royalties for the pharmaceutical version of the... View Details
- 10 Jun 2008
- First Look
First Look: June 10, 2008
Formula’ Harvard Business School Case 808-127 Robert Wessman took over Actavis in 1999 when it was a failing 90-person domestic generic pharmaceutical maker in Iceland. Within 7 years he had brought Actavis to number 5 worldwide, with... View Details
Keywords: Martha Lagace
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
tightly coupled relationships with customers to engage in trials of different product concepts, producers and users can jointly learn about and make sense of the new technology. For instance, Surface Logix, a firm with highly sophisticated, flexible technology called... View Details